Literature DB >> 9796657

In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species.

C J Clancy1, M H Nguyen.   

Abstract

Twenty-nine Aspergillus isolates and 25 Fusarium isolates underwent in vitro antifungal susceptibility testing by a broth macrodilution procedure adapted from the National Committee for Clinical Laboratory Standards guidelines. The MIC50s of both voriconazole and amphotericin B were 0.5 microg/ml and 1 microg/ml against species of Aspergillus and Fusarium, respectively, while the MIC90s of both agents were 1 and 2 microg/ml. Voriconazole was more active in vitro than amphotericin B: the geometric mean MICs of voriconazole and amphotericin B against Aspergillus spp. were 0.36 microg/ml and 0.64 microg/ml, respectively. Voriconazole also demonstrated fungicidal activity against Aspergillus spp., with 86% (24/29) of isolates exhibiting minimum lethal concentrations of < or = 4 microg/ml.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796657     DOI: 10.1007/bf01708622

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  15 in total

1.  In vitro evaluation of voriconazole against some clinically important fungi.

Authors:  M R McGinnis; L Pasarell; D A Sutton; A W Fothergill; C R Cooper; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.

Authors:  D W Denning; D A Stevens
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

3.  Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.

Authors:  A Espinel-Ingroff; M Bartlett; R Bowden; N X Chin; C Cooper; A Fothergill; M R McGinnis; P Menezes; S A Messer; P W Nelson; F C Odds; L Pasarell; J Peter; M A Pfaller; J H Rex; M G Rinaldi; G S Shankland; T J Walsh; I Weitzman
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

4.  Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.

Authors:  M H Nguyen; C J Clancy; V L Yu; Y C Yu; A J Morris; D R Snydman; D A Sutton; M G Rinaldi
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

5.  The emerging role of Fusarium infections in patients with cancer.

Authors:  E Anaissie; H Kantarjian; J Ro; R Hopfer; K Rolston; V Fainstein; G Bodey
Journal:  Medicine (Baltimore)       Date:  1988-03       Impact factor: 1.889

6.  Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.

Authors:  M Murphy; E M Bernard; T Ishimaru; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

7.  In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.

Authors:  S A Radford; E M Johnson; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

8.  In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates.

Authors:  M H Nguyen; C Y Yu
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

9.  In vitro sensitivity of medically significant Fusarium species to various antimycotics.

Authors:  A S Sekhon; A A Padhye; A K Garg; H Ahmad; N Moledina
Journal:  Chemotherapy       Date:  1994 Jul-Aug       Impact factor: 2.544

10.  In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.

Authors:  A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more
  25 in total

Review 1.  Voriconazole: in the treatment of invasive aspergillosis.

Authors:  Richard B R Muijsers; Karen L Goa; Lesley J Scott
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results.

Authors:  Niki I Paphitou; Luis Ostrosky-Zeichner; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 3.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

4.  Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.

Authors:  Lena E Friberg; Patanjali Ravva; Mats O Karlsson; Ping Liu
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

5.  Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

6.  Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.

Authors:  Timothy A Driscoll; Haydar Frangoul; Eneida R Nemecek; Donald K Murphey; Lolie C Yu; Jeffrey Blumer; Robert A Krance; Alice Baruch; Ping Liu
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

7.  Voriconazole is cytotoxic at locally delivered concentrations: a pilot study.

Authors:  Kenneth Schmidt; Alex McLaren; Christine Pauken; Ryan McLemore
Journal:  Clin Orthop Relat Res       Date:  2013-10       Impact factor: 4.176

8.  Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole.

Authors:  A Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

9.  Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.

Authors:  Joseph Meletiadis; Charalampos Antachopoulos; Theodouli Stergiopoulou; Spyros Pournaras; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

10.  Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study.

Authors:  A Espinel-Ingroff; A Fothergill; J Peter; M G Rinaldi; T J Walsh
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.